 | • レポートコード：MRC2203A266 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のコンパニオンアニマル用ワクチン市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、技術別（弱毒生ワクチン、不活化ワクチン、トキソイドワクチン、組換えワクチン、その他）分析、動物種類別（犬、猫、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のコンパニオンアニマル用ワクチン市場規模：技術別（弱毒生ワクチン、不活化ワクチン、トキソイドワクチン、組換えワクチン、その他） ・世界のコンパニオンアニマル用ワクチン市場規模：動物種類別（犬、猫、その他） ・世界のコンパニオンアニマル用ワクチン市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Elanco Animal Health Incorporated、Boehringer Ingelheim GmbH、Brilliant Bio Pharma、…） ・市場機会・将来傾向 |
The companion animal vaccine market was valued at approximately USD 2,768 million in 2020, and it is expected to witness a revenue of USD 3,851 million in 2026, with a CAGR of 5.6% over the forecast period.
The impact of the COVID-19 pandemic on the market is expected to be significant. Certain specific and precautionary guidelines were given to veterinary professionals to treat companion animals during the COVID-19 pandemic by the Centers for Disease Control and Prevention in July 2020. Additionally, many government authorities, such as the Centers for Disease Control and Prevention, recommended veterinary hospitals and clinics to prioritize urgent and emergency visits and procedures. This initiative by such national bodies may reduce the dependence on and usage of diagnostic equipment in veterinary healthcare management. Moreover, according to the OIE (World Organization for Animal Health), most veterinary laboratories are actively involved in testing COVID-19 in humans to overcome the shortage of healthcare facilities and COVID-19 testing laboratories, globally. However, some hospitals and clinics are taking definite measures to avoid the transmission of the virus during this pandemic situation. For instance, Prestige Animal Hospitals has been taking precautionary measures in the treatment of animals. It also introduced a ‘Drop Off Exams’ program that allows the owner to drop off the animal for diagnosis or treatment. The results and treatment plans are then discussed through a phone call/e-mail. Hence, a slight short-term negative impact is witnessed on the companion animal vaccine market, primarily due to the reduced veterinary visits during the COVID-19 outbreak.
The growth of the global companion animal vaccines market is primarily driven by the rising adoption of companion animals, such as dogs and cats, and the increasing cases of zoonotic diseases. At present, companion animals are among the major domesticated animals, and this category is dominated by dogs, cats, and horses. The market studied has been increasingly adopting drug crossovers from the human healthcare sector to the animal healthcare sector, especially dogs and cats. The recent years have observed a significant rise in the number of pet ownership.
According to the annual report of the European Pet Food Industry Association (FEDIAF) in 2020, dogs and cats were found to be the major pets adopted in Europe. Moreover, an estimate of 85 million European households owns at least one pet animal. The trend is further expected to increase during the forecast period.
In the past few years, considering the risk of transferring human diseases to animals and vice versa, the market studied observed increased demand for vaccines for companion animals. New product launches based on emerging technologies, collaborations, mergers and acquisitions, and regional expansions are key strategic initiatives undertaken by these industry players. For instance, in October 2019, Zoetis launched Versican Plus Bb Oral, the first oral vaccine for dogs in Europe, for protection against Bordetella bronchiseptica, a primary component of the canine infectious respiratory disease complex (CIRDC). Thus, due to the development of innovative solutions, the market studied is expected to record significant growth rates.
Key Market Trends
The Live Attenuated Vaccines Segment is Expected to Hold a Major Share over the Forecast Period
Live attenuated vaccines contain a weakened version of the living microbe, making it ineffective to cause diseases. They produce a similar, yet weakened reaction, as compared to that of natural infections. Effective cellular and antibody responses are established by the immune system with single or multiple doses of a vaccination, which aids in providing long-term immunity against infectious pathogens. The live attenuated vaccines are kept refrigerated to sustain their potency. Besides, if the vaccine needs to be shipped overseas or stored by healthcare workers, especially in developing countries that lack widespread refrigeration, a live vaccine may not be the best choice.
Mostly, vaccines licensed for oral or intranasal administration are attenuated. These vaccines must be stored and handled properly, and strict attention must be paid to temperature, even in the lyophilized (free-dried) state. After the reconstitution, the vaccine’s dose should be administered promptly (within one hour) or discarded.
Moreover, the development and launch of new vaccines and a robust pipeline are expected to boost the market growth. For instance, in December 2019, Merck Animal Health launched two new vaccines, namely the Nobivac EDGE DAPPV + L4, a combo vaccine to include parainfluenza protection, and the Nobivac EDGE DAPPV combo vaccine to include parainfluenza protection in dogs. Hence, these vaccines are expected to account for the largest market share during the forecast period.
The North American Companion Animal Vaccine Market is Anticipated to Grow Tremendously over the Forecast Period
The major factors driving the North American companion animal vaccine market include the increasing adoption of companion animals, the surging prevalence of diseases, such as zoonosis, the availability of advanced veterinary healthcare infrastructure, and the presence of key market players, leading to the development of companion vaccines.
The growing pet population, along with an increase in spending on pet care, is fueling the market growth. For instance, according to the 2019-2020 National Pet Owners Survey conducted by the American Pet Products Association (APPA), around 85 million families or 67% of US households owned a pet, up from 56% of US households in 1988. Additionally, during 2019-2020, around 63.4 million US households owned a dog.
Moreover, as per the American Pet Products Association, in 2020, it was estimated that around USD 99.0 billion was spent on pets in the United States, up from USD 95.7 billion in 2019. Furthermore, the Centers for Disease Control and Prevention (CDC), the Department of the Interior (DOI) and the US Department of Agriculture (USDA) released a 2019 report, listing the zoonotic diseases of the highest concern in the United States. This factor may boost the market growth, as it may increase the demand for vaccines to eradicate infectious diseases in companion animals.
To increase their market shares, market players are adopting various strategies, such as product launches, product developments, collaborations, mergers, acquisitions, and expansions. For instance, in October 2020, Elanco signed an agreement with Bayer’s Animal Health Business to acquire its Animal Health business in a transaction valued at USD 7.6 billion. Thus, the rising incidence rates of infectious diseases in companion animals, along with increasing product launches, may show significant market growth over the forecast period.
Competitive Landscape
The companion animal vaccine market is moderately consolidated. In terms of market share, major players, such as Elanco Animal Health Incorporated, Boehringer Ingelheim GmbH, Merck & Co. Inc., Zoetis Inc., and Bioveta AS, among others, hold the largest market shares. Key players are evolving through various strategic alliances, such as acquisitions, collaborations, and new product launches, to expand the global product portfolios and secure their positions in the global market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of Companion Animals, such as Dogs and Cats
4.2.2 Increasing Cases of Zoonotic Diseases
4.3 Market Restraints
4.3.1 High Cost of Vaccine Development and Regulatory Concern
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Live Attenuated Vaccines
5.1.2 Inactivated Vaccines
5.1.3 Toxoid Vaccines
5.1.4 Recombinant Vaccines
5.1.5 Other Technologies
5.2 By Animal Type
5.2.1 Dogs
5.2.2 Cats
5.2.3 Other Animal Types
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 COMPANY PROFILES
6.1.1 Elanco Animal Health Incorporated
6.1.2 Boehringer Ingelheim GmbH
6.1.3 Brilliant Bio Pharma
6.1.4 Merck & Co. Inc.
6.1.5 Virbac
6.1.6 Zoetis Inc.
6.1.7 Indian Immunologicals Ltd
6.1.8 Bioveta AS
6.1.9 Vetoquinol SA
6.1.10 Merial (Sanofi)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS